Loading...

MRKR MARKER THERAPEUTICS INC Product Launches 8-K Filing

MRKR

MRKR

MARKER THERAPEUTICS INC

(MRKR)

2025 8-K

Summary

Summary

Patient Treatment Announcement

Clinical Study Update

New Product Launches

Financial Results

Stockholder Meeting

Stock Options Awarded

Director Resignation

Private Placement Funding

Private Placement

Financial Results

Financial Results

NIH Grant Award

Annual Meeting and Terminat...

Financial Results

Clinical Presentation at Me...

Financial Results

Termination of Purchase Agr...

Agreement for Product Supply

Participation Announcement

Management Change

Financial Results and Updates

Financial Results

Appointments, Resignations

Completion of Acquisition o...

Annual Meeting of Stockholders

Acquisition, CEO Resignation

Financial Results and Updates

Resignation of Chief Medica...

Reverse Stock Split and Sha...

External Links:

On May 20, 2025, Marker Therapeutics, Inc. announced that data from their Phase 1 study of MT-601 shows lymphodepletion enhances the growth and persistence of specialized T-cells in lymphoma patients.

AI Assistant

MARKER THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.